Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
M834 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| M834 | BIOLOGICAL | - |
| US-Sourced Orencia® | BIOLOGICAL | - |
| EU-Sourced Orencia® | BIOLOGICAL | - |
M834 is an investigational monoclonal antibody developed by Johnson & Johnson. It has been studied in a Phase 1 clinical trial in healthy volunteers. The specific disease indications for M834 have not been disclosed, and the compound remains in early clinical development.
M834 is developed by Johnson & Johnson, which trades on the New York Stock Exchange under the ticker JNJ. The company sponsored the Phase 1 study of M834 in healthy subjects. No partnership or licensing arrangement for the asset has been announced.
M834 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The program has not advanced beyond early-stage testing, and M834 is not approved by the FDA for any indication.
M834 has been evaluated in one completed Phase 1 trial, NCT02923583, titled Assessment of Pharmacokinetics (PK) and Safety of M834 and Orencia, in Healthy Subjects. The study enrolled 243 healthy volunteers and used an uncontrolled design without randomization or blinding.
No. M834 and Orencia are separate products. The Phase 1 trial NCT02923583 assessed the pharmacokinetics and safety of both M834 and Orencia in healthy subjects, which means the two were studied alongside each other rather than being the same molecule.